Page 11 - Annual Report 2020
P. 11
Current research projects:
1) Novelcombinationtherapyinhigh grade serous ovarian cancer- dual inhibition of ALDH1A and MEK1/2
2) Novelcompoundsthattarget Oxidative Phosphorylation as a preferable source of energy of ovarian cancer stem cells
3) Effectofexosomesonovarian cancer cell, purification and characterization
pan-Caspase inhibitor ZVAD-FMK. This requires the kinase activity of receptor-interacting pro- teins 1 and 3 (RIPK1 and RIPK3) to follow their downstream target MLKL. Necroptosis execution involves formation of micro-complex (20 MDa) necroptosome followed by disintegration of mitochondrial and plasma membranes. Despite necroptosis importance, many molecular down- stream events are unknown or being disputed.
elevated expression of anti-apoptotic proteins. Thus, elucidation of necroptosis/cell proliferation or necroptosis/apoptosis balance is essential to trigger cancer cell death or prevent pathological conditions such as ischemia or inflammation. The most studied kind of necroptosis is initiated by TNF-α while Caspases are inhibited using
Figure 2: Self renewal and differentiation capacity of Cancer Stem cells.
Invited seminars:
1) ANovelPan-ALDH1AInhibitorInduces Necroptosis in Ovarian Cancer Stem-Like cells. September 21st, 2017.
Mayo Clinic, Ovarian cancer spore group
2) ANovelPan-ALDH1AInhibitor
Induces Necroptosis in Ovarian Cancer Stem-Like cells. June, 2018. University of Chicago, OBGYN department
Figure 1: Transmission Electronic Microscopy of mitochondria.
THE HORMEL INSTITUTE // UNIVERSITY OF MINNESOTA PG 11
